PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsB-cell lymphoma
MeSH D016393 - b-cell lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008228:Non-hodgkin lymphoma
57 Companies
25 Drugs
$
Success rate
D016393: 
B-cell lymphoma
15 Companies
7 Drugs
$
Success rate
D002051:Burkitt lymphoma
21 Companies
1 Drug
$
Success rate
D008230:Lymphomatoid granulomatosis
1 Company
1 Drug
$
Success rate
D016403:Large b-cell lymphoma diffuse
10 Companies
8 Drugs
$
Success rate
D016483:Aids-related lymphoma
0 Companies
0 Drugs
Success rate
D018442:B-cell lymphoma marginal zone
1 Company
1 Drug
$
Success rate
D054685:Primary effusion lymphoma
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Johnson & JohnsonIbrutinib Imbruvica  2014-10-21 $2,964 M Q2/24-Q1/25 
RocheRituximab MabThera  1998-06-02   
Polatuzumab vedotin Polivy  2020-01-16 $888.887 M Q4/22-Q3/23 
SandozRituximab Rixathon  2017-06-15   
Rituximab Riximyo  2017-06-15   
PfizerRituximab Ruxience  2019-07-23 $390 M Y2023 
Zydus TherapeuticsIbrutinib Ibrutinib  2021-03-31   
Bristol Myers SquibbLisocabtagene maraleucel Breyanzi  2022-04-04 $1,229 M Q4/24-Q3/25 
BiogenRituximab Rituxan  2002-02-19   
CelltrionRituximab Blitzima  2017-07-13   
Rituximab Ritemvia  2017-07-13   
Rituximab Rituzena (previously Tuxella)  2017-07-13   
Rituximab Truxima  2018-11-28   
GenentechRituximab Rituxan  1997-11-26   
Rituximab, Hyaluronidase (human recombinant) Rituxan Hycela  2017-06-22   
PharmacyclicsIbrutinib Imbruvica 2026-12-28 2013-11-13 $312.698 M Q2/14-Q1/15 
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
79%
74/94
Phase 2
21%
23/111
Phase 3
20%
7/35
Approved: 6Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
Ibrutinib,
Benzimidazole,
Abexinostat,
Buparlisib,
Lornoxicam,
Aspartame,
Bevifimod,
Palifosfamide,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Doxorubin,
Iphosphamid,
Cort-108297,
Hydroxydaunomycin
Roche
Rituximab,
Polatuzumab vedotin,
Benzimidazole,
Tiragolumab,
Rimiducid,
Lenograstim,
Edrecolomab,
Lornoxicam,
Vindesine,
Aspartame,
Bevifimod,
Doxecitine,
Nepidermin,
Palifosfamide,
Selicrelumab,
Fludeoxyglucose f-18,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Anthracycline,
Rituxumab,
Aminoglycoside,
Doxorubin,
Iphosphamid,
Solumedrol,
Hydroxydaunomycin
Sandoz
Rituximab,
Lenograstim,
Molgramostim
Pfizer
Rituximab,
Benzimidazole,
Utomilumab,
Lornoxicam,
Bevifimod,
Doxecitine,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Pd0332991,
Solumedrol,
Histone-arginine methyltransferase carm1,
Surlorian
Bristol Myers Squibb
Lisocabtagene maraleucel,
Gilvetmab,
Epacadostat,
Lornoxicam,
Bevifimod,
URELUMAB,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Doxorubin,
Ibi301,
Cort-108297,
Histone-arginine methyltransferase carm1,
Hydroxydaunomycin
Biogen
Rituximab,
Globulin, immune
Celltrion
Rituximab
Genentech
Rituximab,
Hyaluronidase (human recombinant),
Fluorodopa f-18,
Benzimidazole,
Tiragolumab,
Fenebrutinib,
Navitoclax,
Lenograstim,
Calcium dobesilate,
Doconexent,
Lornoxicam,
Imgatuzumab,
Aspartame,
Bevifimod,
Lotamilast,
Nadide,
Nepidermin,
Palifosfamide,
Remetinostat,
TAPOTOCLAX,
Usistapide,
Fludeoxyglucose f-18,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Doxorubin,
Iphosphamid,
Cort-108297,
Solumedrol,
Hydroxydaunomycin,
Cc5013,
Mephedrone,
Isoxaflutole,
Sominex
Pharmacyclics
Ibrutinib,
Lornoxicam,
Zilovertamab,
Imgatuzumab,
Aspartame,
Bevifimod,
Palifosfamide,
Globulin, immune,
Anthracycline,
Aminoglycoside,
Doxorubin,
Iphosphamid,
Histone-arginine methyltransferase carm1,
Hydroxydaunomycin,
Surlorian,
Cc5013
Celgene
Lisocabtagene maraleucel,
Melarsoprol,
Benzimidazole,
Iberdomide,
Lenograstim,
Calcium dobesilate,
Phenylalanine,
Doconexent,
Lornoxicam,
Imgatuzumab,
Pegargiminase,
Aspartame,
AVADOMIDE,
Bevifimod,
Doxecitine,
MOTOLIMOD,
Palifosfamide,
SPEBRUTINIB,
Retinol,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Anthracycline,
Aminoglycoside,
Doxorubin,
Iphosphamid,
Solumedrol,
Pyridoxal,
Gemcis,
Hydroxydaunomycin,
Cc5013,
Caphosol
Acrotech Biopharma
Methylcobalamin,
Bevifimod,
Doxecitine,
Nadide,
Polyglycolic acid,
Retinol
Amgen
Rituximab,
Lenograstim,
Lornoxicam,
Molgramostim,
Pegargiminase,
Bevifimod,
Nepidermin,
TAPOTOCLAX,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Krestin,
Doxorubin,
Hydroxydaunomycin,
Cc5013
Orphan Medical
Lornoxicam,
Bevifimod,
Globulin, immune
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use